Janssen(J&J) Signs an Exclusive Worldwide License Agreement with MeiraGTx for its Gene Therapy Candidates

Shots:

• Janssen to get exclusive WW license rights to develop & commercialize certain clinical candidates in MeiraGTx’s inherited retinal disease pipeline. Janssen also has an option to license the portfolio of products for gene targeting in inherited retinal disease, will be developed in collaboration with MeiraGTx
• The focus of the collaboration is to develop adeno-associated virus (AAV) technology exploring targets for delivering treatments in inherited retinal diseases including achromatopsia (ACHM) caused by mutations in CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP)
• AAV-CNGB3 and AAV-CNGA3 are gene therapy candidates administered via subretinal IV in the eye. AAV-CNGB3 has also received FDA’s ODD & FT designation for achromatopsia caused by mutations in the CNGB3 gene, evaluated in P-I/II in adults and pediatrics

Click here to read full press release/ article | Ref: Janssen | Image: Opthalmology Innovation Summit